DNA graphic

Search Results

You searched for: lupus nephritis
Results found: 177

Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy

San Francisco, CA- June 20. The Lupus Research Alliance (LRA) announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment. Drs. Radic and Schett […]

Lupus Innovation Award (LIA)

The Lupus Innovation Award ($300,000 for 2 years) provides early-stage support for highly innovative approaches to major challenges in lupus research. If you are a researcher and would like to learn more about our funded research please click here.

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […]

Good News on Lupus Nephritis Discoveries from ACR Convergence 2020

November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE).  AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […]

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory […]

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

NEW YORK, N.Y. — [March 14, 2024]: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation […]

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […]
Stay informed about events, research developments, and ways you can help. Sign up for updates